1354691-47-6 Usage
Description
[(3S)-3-hydroxypyrrolidin-1-yl](oxan-4-yl)Methanone, also known as (S)-Mepiramine, is a chemical compound that functions as an antihistamine and anticholinergic agent. It has a molecular formula of C14H21NO2 and a molecular weight of 231.32 g/mol. [(3S)-3-hydroxypyrrolidin-1-yl](oxan-4-yl)Methanone operates by inhibiting the effects of histamine, which is instrumental in reducing allergy symptoms such as itching, sneezing, and a runny nose. Additionally, its anticholinergic properties allow it to impede the effects of acetylcholine, thereby mitigating symptoms of motion sickness and nausea.
Uses
Used in Pharmaceutical Industry:
[(3S)-3-hydroxypyrrolidin-1-yl](oxan-4-yl)Methanone is utilized as an active pharmaceutical ingredient for allergy relief and motion sickness treatments. Its dual functionality as an antihistamine and anticholinergic agent makes it a versatile compound for addressing a range of symptoms associated with allergies and motion sickness.
Used in Over-the-Counter Medications:
[(3S)-3-hydroxypyrrolidin-1-yl](oxan-4-yl)Methanone is incorporated into over-the-counter medications, making it accessible to consumers seeking relief from allergy symptoms without a prescription. Its widespread availability and well-tolerated nature contribute to its popularity in non-prescription remedies.
Used in Prescription Medications:
In addition to over-the-counter applications, [(3S)-3-hydroxypyrrolidin-1-yl](oxan-4-yl)Methanone is also used in prescription medications, particularly for cases where stronger intervention is required or for individuals with more severe symptoms that do not respond adequately to over-the-counter treatments.
Overall, [(3S)-3-hydroxypyrrolidin-1-yl](oxan-4-yl)Methanone, or (S)-Mepiramine, is a valuable compound in the pharmaceutical industry due to its effectiveness in treating allergy symptoms and motion sickness, as well as its favorable safety profile.
Check Digit Verification of cas no
The CAS Registry Mumber 1354691-47-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,4,6,9 and 1 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1354691-47:
(9*1)+(8*3)+(7*5)+(6*4)+(5*6)+(4*9)+(3*1)+(2*4)+(1*7)=176
176 % 10 = 6
So 1354691-47-6 is a valid CAS Registry Number.
1354691-47-6Relevant articles and documents
Projected Dose Optimization of Amino- And Hydroxypyrrolidine Purine PI3KδImmunomodulators
Methot, Joey L.,Zhou, Hua,McGowan, Meredeth A.,Anthony, Neville John,Christopher, Matthew,Garcia, Yudith,Achab, Abdelghani,Lipford, Kathryn,Trotter, Benjamin Wesley,Altman, Michael D.,Fradera, Xavier,Lesburg, Charles A.,Li, Chaomin,Alves, Stephen,Chappell, Craig P.,Jain, Renu,Mangado, Ruban,Pinheiro, Elaine,Williams, Sybill M. G.,Goldenblatt, Peter,Hill, Armetta,Shaffer, Lynsey,Chen, Dapeng,Tong, Vincent,McLeod, Robbie L.,Lee, Hyun-Hee,Yu, Hongshi,Shah, Sanjiv,Katz, Jason D.
, p. 5137 - 5156 (2021)
The approvals of idelalisib and duvelisib have validated PI3Kδinhibitors for the treatment for hematological malignancies driven by the PI3K/AKT pathway. Our program led to the identification of structurally distinct heterocycloalkyl purine inhibitors wit
Use of Inhibitors of the Activity or Function of PI3K
-
Paragraph 0808, (2016/01/09)
The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.
SOLID FORMS AND SALTS OF TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES
-
Page/Page column 38, (2013/03/26)
The invention relates to crystalline anhydrous forms, crystalline solvate forms and/or salt forms including crystalline salt forms of {(S)-3-[6-(6-methoxy-5-methyl-pyridin-3-yl)-5,6,7,8- tetrahydro-pyrido[4,3-d]pyrimidin-4-yloxy]-pyrrolidin-1-yl}-(tetrahydro-pyran-4-yl)-methanone or salt forms including crystalline salt forms of 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl- pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-on; pharmaceutical compositions and combinations including these forms as well as to methods of using these forms, including their pharmaceutical compositions and combinations for the treatment of diseases.
